A recent study indicates that patients who come off new weight-loss injections like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who halt traditional lifestyle regimens.
Findings released in a leading medical journal demonstrates that while obese individuals can lose substantial amounts of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Individuals buying these drugs must be informed of the potential of quick rebound weight gain when the medication ends," cautioned researcher Dr. Susan Jebb.
Such speed of regain implies a reversion to original weight in about one and a half years.
Analyzing Treatments
The research, which looked at dozens of studies involving thousands of patients, compared the effects of GLP-1 agonists with older methods.
The team note that people who lose weight through lifestyle changes alone usually experience a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
Explaining the Fast Regain
Nutrition scientists believe the mechanism of the drugs is key to understanding the accelerated weight return.
These medications copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication means hunger is no longer kept in check, making overeating far more likely."
A Lifelong Issue?
Health authorities recommend the jabs for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians say that, given the significant potential of relapse, the therapy should be considered long-term.
This perspective is supported by drug manufacturers, who say that the findings "underscore the long-term nature of obesity," similar to managing conditions like high blood pressure.
User Testimonies
People who have discontinued the medication describe a powerful return of hunger.
"I experienced something that goes on and I was suddenly starving," recalled an individual.
This challenge is compounded if users have not developed permanent dietary or behavioural changes during treatment.
Growing Adoption
Survey data show that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Use is higher among females compared to men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Ultimately, researchers caution that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone cure and lasting health benefits likely depends on integrated lifestyle support.
